Cancers & treatments·Regimen libraryFirst line

Carboplatin + etoposide + atezolizumab (or durvalumab)

Checked 2026-09-09

Extensive-stage SCLC, first line

One cycle

every 21 days × 4 · about 12 weeks in total

21-day cycle × 4, then checkpoint inhibitor maintenance until progression (about 12 weeks)Intravenous

Components

Drug	Dose	Route	Days
Carboplatin Cytotoxic chemotherapy (platinum)	AUC 5	IV	D1
Etoposide Topoisomerase II inhibitor (podophyllotoxin derivative)	100 mg/m²	IV	D1-3
Atezolizumab 1,200 mg (IMpower133) or durvalumab 1,500 mg (CASPIAN) Monoclonal antibody (anti-PD-L1)	day 1; maintenance every 3-4 weeks	IV	D1

Cycles

4, then checkpoint inhibitor maintenance until progression

21-day cycle

Emetogenicity

Moderate (30-90%)

G-CSF

Not routine

Notes

IMforte: lurbinectedin added to atezolizumab maintenance improves PFS and OS.

Used in

Small-cell lung cancer

Trials

IMpower133 CASPIAN IMforte

Products

Platinum + etoposide (EP / CE)DurvalumabCarboplatinEtoposideAtezolizumab

Source

IMpower133, NEJM 2018

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Cisplatin + etoposide (EP)

Limited-stage SCLC with concurrent thoracic radiotherapy; stage III NSCLC chemoradiation; high-grade neuroendocrine carcinoma

every 21 days × 4

Topotecan

Relapsed SCLC; platinum-resistant ovarian or cervical cancer

every 21 days

Tarlatamab

Extensive-stage SCLC after platinum-based chemotherapy

every 14 days

All regimens Topotecan →